Date:9/10/2010

tter(); } function readCookie(name){ var cookieValue = ""; var search = name + "="; if(document.cookie.length > 0){ offset = document.cookie.indexOf(search); if (offset != -1){ offset += search.length; end = document.cookie.indexOf(";", offset); if (end == -1) end = document.cookie.length; cookieValue = unescape(document.cookie.substring(offset, end)) } } return cookieValue; } window.onload=function(){ OnNewsreleaseLoad(); var userid = readCookie('DMUserTrack'); var csid = 102618354; var newstogramURL = 'http://www.prnewswire.com/templates/PRN_MultiVu_URL_Reader?userid='+userid+'&csid='+csid; //var newstogramURL ='http://www.prnewswire.com/templates/prnwConfig.xml'; var delay = function() { sendToFlash('StartPlay',newstogramURL); }; setTimeout(delay,100,"JavaScript"); //setTimeout("sendToFlash('StartPlay', 'http://www.prnewswire.com/templates/prnwConfig.xml')",100); }; function ShortenURL() { //Bit.ly function call to shorten url BitlyClient.call('shorten', {'longUrl': formatURL()}, 'BitlyCB.alertResponse'); }

Advanced Search Search

Products & Services   

SOURCE China-Biotics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. China-Biotics, Inc. Announces US$20 million Share Buyback Program
2. China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
3. China-Biotics, Inc. Begins Trial Production at New Facility, Affirms 2010 Revenue Guidance
4. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
5. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
6. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
7. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
8. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
9. Endologix Comments on Alleged Patent Infringement
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ACRO Comments on NEJM Article on Globalization of Clinical Research